BRIEF-Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Reuters02-28

Feb 28 (Reuters) - Incannex Healthcare Inc :

* INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY DISORDER

* INCANNEX HEALTHCARE INC - PSIGAD1 TRIAL ACHIEVES PRIMARY ENDPOINT

* INCANNEX HEALTHCARE INC - PSIGAD PSILOCYBIN-ASSISTED THERAPY DEMONSTRATED A STATISTICALLY SIGNIFICANT HAM-A REDUCTION OF 12.8 POINTS FROM BASELINE

* INCANNEX HEALTHCARE - NEWLY DEVELOPED AND FORMULATED PSX-001 PSILOCYBIN DRUG PRODUCT FINALISED - CGMP MANUFACTURE FOR CLINICAL TRIAL SUPPLY UNDERWAY

* INCANNEX HEALTHCARE INC - O SUBMIT AN INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION WITH U.S. FDA TO PROCEED TO A MULTI-SITE PHASE 2B TRIAL

* INCANNEX HEALTHCARE - 44% OF PATIENTS IN PSILOCYBIN GROUP AHOWED AT LEAST 50% REDUCTION IN ANXIETY SCORE AND 27% OF PATIENTS SHOWED DISEASE REMISSION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2414979323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-28 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2414979323","market":"us","top_or_hot":-1,"title":"BRIEF-Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder","media":"Reuters","content":"<html><body><p>Feb 28 (Reuters) - Incannex Healthcare Inc   :</p><p>   * INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY DISORDER</p><p>   * INCANNEX HEALTHCARE INC - PSIGAD1 TRIAL ACHIEVES PRIMARY ENDPOINT</p><p>   * INCANNEX HEALTHCARE INC - PSIGAD PSILOCYBIN-ASSISTED THERAPY DEMONSTRATED A STATISTICALLY SIGNIFICANT HAM-A REDUCTION OF 12.8 POINTS FROM BASELINE</p><p>   * INCANNEX HEALTHCARE - NEWLY DEVELOPED AND FORMULATED PSX-001 PSILOCYBIN DRUG PRODUCT FINALISED - CGMP MANUFACTURE FOR CLINICAL TRIAL SUPPLY UNDERWAY</p><p>   * INCANNEX HEALTHCARE INC - O SUBMIT AN INVESTIGATIONAL NEW DRUG <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> APPLICATION WITH U.S. FDA TO PROCEED TO A MULTI-SITE PHASE 2B TRIAL</p><p>   * INCANNEX HEALTHCARE - 44% OF PATIENTS IN PSILOCYBIN GROUP AHOWED AT LEAST 50% REDUCTION IN ANXIETY SCORE AND 27% OF PATIENTS SHOWED DISEASE REMISSION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-28 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 28 (Reuters) - Incannex Healthcare Inc   :   * INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY DISORDER   * INCANNEX ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2414979323","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2414979323","pubTimestamp":1709123988,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 28  - Incannex Healthcare Inc   :   * INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY DISORDER   * INCANNEX HEALTHCARE INC - PSIGAD1 TRIAL ACHIEVES PRIMARY ENDPOINT   * INCANNEX HEALTHCARE INC - PSIGAD PSILOCYBIN-ASSISTED THERAPY DEMONSTRATED A STATISTICALLY SIGNIFICANT HAM-A REDUCTION OF 12.8 POINTS FROM BASELINE   * INCANNEX HEALTHCARE - NEWLY DEVELOPED AND FORMULATED PSX-001 PSILOCYBIN DRUG PRODUCT FINALISED - CGMP MANUFACTURE FOR CLINICAL TRIAL SUPPLY UNDERWAY   * INCANNEX HEALTHCARE INC - O SUBMIT AN INVESTIGATIONAL NEW DRUG  APPLICATION WITH U.S. FDA TO PROCEED TO A MULTI-SITE PHASE 2B TRIAL   * INCANNEX HEALTHCARE - 44% OF PATIENTS IN PSILOCYBIN GROUP AHOWED AT LEAST 50% REDUCTION IN ANXIETY SCORE AND 27% OF PATIENTS SHOWED DISEASE REMISSIONSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IXHL":"INCANNEX HEALTHCARE LTD"},"translate_title":"简介——Incannex宣布裸盖菇素治疗广泛性焦虑症的2期Psi-GAD1临床试验结果为阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Feb 28 (Reuters) - Incannex Healthcare Inc   :   * INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY DISORDER   * INCANNEX HEALTHCARE INC - PSIGAD1 TRIAL ACHIEVES PRIMARY ENDPOINT   * INCANNEX HEALTHCARE INC - PSIGAD PSILOCYBIN-ASSISTED THERAPY DEMONSTRATED A STATISTICALLY SIGNIFICANT HAM-A REDUCTION OF 12.8 POINTS FROM BASELINE   * INCANNEX HEALTHCARE - NEWLY DEVELOPED AND FORMULATED PSX-001 PSILOCYBIN DRUG PRODUCT FINALISED - CGMP MANUFACTURE FOR CLINICAL TRIAL SUPPLY UNDERWAY   * INCANNEX HEALTHCARE INC - O SUBMIT AN INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION WITH U.S. FDA TO PROCEED TO A MULTI-SITE PHASE 2B TRIAL   * INCANNEX HEALTHCARE - 44% OF PATIENTS IN PSILOCYBIN GROUP AHOWED AT LEAST 50% REDUCTION IN ANXIETY SCORE AND 27% OF PATIENTS SHOWED DISEASE REMISSIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2414979323"}